StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report released on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.
TRACON Pharmaceuticals Price Performance
TCON stock opened at $0.05 on Tuesday. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75. The company has a fifty day simple moving average of $0.09 and a two-hundred day simple moving average of $0.68. The firm has a market capitalization of $163,652.72, a P/E ratio of 0.01 and a beta of 1.43.
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The business had revenue of $0.06 million for the quarter.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Articles
- Five stocks we like better than TRACON Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- 3 Monster Growth Stocks to Buy Now
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Manufacturing Stocks Investing
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
